Cambridge, UK, 6 March 2017 - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that one of the ‘Abzena inside’ Composite Human Antibody™ products previously disclosed as being in Phase I trials is moving forwards into a Phase II clinical trial.
The product is being developed by an un-named major US pharmaceutical company for the treatment of neurodegenerative conditions and has been studied to date in two Phase I clinical trials.
Dr John Burt, Abzena’s CEO, said:
“We are pleased to see the progression of this ‘Abzena inside’ product into Phase II clinical development following the recent similar announcements about two other ‘Abzena inside’ products. This illustrates the strength we have in the portfolio of products that our partners are developing based on our antibody engineering technology.”
